title: Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.
abstract: OBJECTIVE
  To investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).
  
  
  METHODS
  The study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total drusen area from baseline.
  
  
  RESULTS
  Study drug was well tolerated and was associated with few adverse events. The mean change in BCVA at 2 years was +0.2 ± 13.3 letters in the study eyes and -11.3 ± 7.6 letters in fellow eyes (P = 0.0259). However, no statistically significant differences were found between the study and fellow eyes for all other secondary outcome measures.
  
  
  CONCLUSIONS
  OT-551 was well tolerated by study participants and was not associated with any serious adverse effects. Efficacy measurements in this small study indicate a possible effect in maintaining visual acuity. However, the absence of significant effects on other outcomes measures in this study suggests that OT-551, in the current concentration and mode of delivery, may have limited or no benefit as a treatment for GA (ClinicalTrials.gov number, NCT00306488).
authors.affiliation: Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. wongw@xnei.nih.gov
authors.forename: Wai T
authors.initials: WT
authors.lastname: Wong
authors.forename: Waynekid
authors.initials: W
authors.lastname: Kam
authors.forename: Denise
authors.initials: D
authors.lastname: Cunningham
authors.forename: Molly
authors.initials: M
authors.lastname: Harrington
authors.forename: Keri
authors.initials: K
authors.lastname: Hammel
authors.forename: Catherine B
authors.initials: CB
authors.lastname: Meyerle
authors.forename: Catherine
authors.initials: C
authors.lastname: Cukras
authors.forename: Emily Y
authors.initials: EY
authors.lastname: Chew
authors.forename: Srinivas R
authors.initials: SR
authors.lastname: Sadda
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Ferris
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000975:Antioxidants / Q000008:administration & dosage* / Q000009:adverse effects; D015350:Contrast Sensitivity; D005260:Female; D057092:Geographic Atrophy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010865:Pilot Projects; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; C550190:OT-551; D010880:Piperidines